Shared from twixb · endpts.com
Biopharma sentiment has reached its highest level since the downturn, reflecting a positive shift in the industry. This optimism is particularly evident in the wearables sector, where companies are increasingly focusing on GLP-1 medications in their strategies.
This content does not provide any relevant insights specific to the reader's interests in healthtech, biotech, digital health, telemedicine, AI drug discovery, or related fields.
Powered by twixb
twixb tracks your favorite blogs and social media, filters by keywords, and delivers personalized key learnings — straight to your inbox.
Recent stories curated alongside this one.
Northwell Health has integrated a firearm injury risk screening tool into Epic's electronic health record system, aimed at identifying patients at risk of firearm injuries, providing them with gun locks, and referring them to intervention services. This initiative is part of a broader effort to enhance patient safety and prevent gun violence through real-time clinical interventions.
Shionogi has received FDA approval for its oral antiviral pill designed to prevent COVID-19 in both adults and children following exposure, marking a significant advancement in COVID-19 treatment options.
At ASCO 2026, GSK introduced velzatinib, a new tyrosine kinase inhibitor aimed at treating gastrointestinal stromal tumors (GISTs), which could potentially redefine standard care by effectively targeting both primary and secondary mutations in the c-KIT enzyme. Preliminary results showed promising tumor shrinkage rates in patients, positioning velzatinib as a potential improvement over existing treatments like Gleevec and Sutent.
Recent data presented at the American Society of Clinical Oncology (ASCO) meeting highlights significant advancements in cancer treatment, including the pancreatic cancer drug daraxonrasib, which improves median overall survival by 60% compared to standard chemotherapy. Additionally, the meeting showcased the growing influence of China's biotechnology sector, marking a notable shift in global drug development dynamics.
Revolution Medicines is making significant strides in pancreatic cancer treatment with the early access rollout of their experimental drug, daraxonrasib, which has shown promising results at the ASCO conference. Additionally, Eli Lilly announced two deals in China and Akeso's lung cancer therapy continues to exceed expectations, marking a notable period in biotech advancements.
